Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

12,101 total articles

Lipocine Director Purchases 123,000 Shares Amid Mixed Clinical News

Lipocine Director Purchases 123,000 Shares Amid Mixed Clinical News

Director Higuchi John W. bought 123,000 shares of Lipocine Inc. (NASDAQ: LPCN) on April 6, 2026, for $2.05 per share, a transaction totaling $252,149. The purchase brings his direct holdings to 163,797 shares. The transaction coincides with the stock trading close to a 52-week low, and follows Phase 3 trial results for LPCN 1154 that missed the pri…

Kinder Morgan Vice President Disposes of $203K in Class P Shares

Kinder Morgan Vice President Disposes of $203K in Class P Shares

John W. Schlosser, Vice President and President, Terminals at Kinder Morgan, sold 6,166 shares of Class P common stock on April 6, 2026, for roughly $203,071 under a pre-established 10b5-1 plan. The disposal occurred while KMI shares trade near a 52-week high and amid a patchwork of recent analyst revisions and corporate pipeline developments.

Energy Recovery Director Sells $1.67 Million in ERII Shares as Company Reports Q4 Miss and Lowers 2026 Outlook

Energy Recovery Director Sells $1.67 Million in ERII Shares as Company Reports Q4 Miss and Lowers 2026 Outlook

Arve Hanstveit, a director at Energy Recovery, Inc. (NASDAQ: ERII), sold 165,292 shares on April 2, 2026, for roughly $1.67 million at $10.14 per share. The disposition was executed by a broker without Hanstveit's instruction to satisfy a margin call on shares pledged as collateral. The transaction comes as Energy Recovery reported fourth-quarter 2…

Lightwave Logic Director Sells $76,680 in Stock to Cover RSU Taxes as Company Reports Strong Q4 Revenue Growth

Lightwave Logic Director Sells $76,680 in Stock to Cover RSU Taxes as Company Reports Strong Q4 Revenue Growth

Lightwave Logic director Thomas M. Connelly Jr. sold 9,000 shares of common stock on April 6, 2026, for $8.52 per share, yielding $76,680. The sale, disclosed on a Form 4, was made to meet tax-withholding obligations tied to restricted stock unit vestings on March 31, 2026. The move comes as Lightwave Logic's stock has climbed 786% over the past ye…

Arteris CFO Sells Shares to Cover RSU Taxes After Strong Quarter; Stock Seen as Overvalued by InvestingPro

Arteris CFO Sells Shares to Cover RSU Taxes After Strong Quarter; Stock Seen as Overvalued by InvestingPro

Arteris, Inc. CFO Nicholas B. Hawkins disposed of 5,870 shares on April 2, 2026, in multiple transactions disclosed on a Form 4, raising $85,969. The sales were reported as tax-covering actions tied to the vesting of restricted stock units. Arteris recently posted better-than-expected fourth-quarter 2025 results, while InvestingPro flags the stock …

Altimmune Director Increases Stake with $31,349 Purchase

Altimmune Director Increases Stake with $31,349 Purchase

Altimmune director John Gill purchased 9,200 shares of company stock on April 6, 2026, paying between $3.4050 and $3.4080 per share for a total of $31,349. The transaction occurred while the shares have climbed more than 15% in the prior week. The company recently posted fourth-quarter 2025 results that missed expectations on both EPS and revenue, …

Lands’ End CFO Disposes of Shares Amid Stock Volatility; Company Posts Q4 Miss and Approves Buyback

Lands’ End CFO Disposes of Shares Amid Stock Volatility; Company Posts Q4 Miss and Approves Buyback

Lands’ End CFO and Treasurer Bernard Louis McCracken III sold 3,362 shares of common stock on April 1, 2026, at $45 per share, totaling $151,290, while exercising and receiving additional shares at no cost. The transactions occurred as the stock trades well below that sale price and after the company reported a fourth-quarter earnings and revenue m…

Beam Therapeutics Treasurer Sells $79,688 of Stock as Clinical Data and Analyst Upgrades Gain Traction

Beam Therapeutics Treasurer Sells $79,688 of Stock as Clinical Data and Analyst Upgrades Gain Traction

Bethany Cavanagh, Beam Therapeutics' SVP of Finance and Treasurer, sold 3,242 shares on April 1, 2026, under a Rule 10b5-1 plan to meet tax withholding obligations tied to RSU vesting. The transaction totaled $79,688. Beam has recently disclosed clinical data from its BEACON sickle cell program and BEAM-302 alpha-1 antitrypsin deficiency study, pro…